This proof - of - concept study, which tested MVA, Ad26, and Ad35 vector - based vaccines, is the first to show
partial vaccine protection in the stringent animal model involving heterologous, neutralization - resistant SIVmac251 viral challenges in rhesus monkeys.
Not exact matches
Those trials will test the safety and feasibility of giving children four doses of the
vaccine, which provides only
partial protection against the disease.
A malaria
vaccine is available, but its
protection is only
partial and temporary, and like antimalarial medicines, the
vaccine has a limited supply.
Nevertheless, a
vaccine that offers even
partial protection will be welcome against a disease that kills 3 million people a year.
That's the question posed by researchers in the journal BMC Immunology, who think that the
vaccine might have offered
partial protection against HIV.
«We previously showed that adenovirus vector - based HIV - 1
vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical
vaccine candidates offered
partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and
Vaccine Research at BIDMC and professor of medicine at Harvard Medical
Vaccine Research at BIDMC and professor of medicine at Harvard Medical School.
The eagerly awaited results from the world's first large - scale trial of a malaria
vaccine are in, and they confirm what other, smaller studies had shown: The
vaccine, called RTS, S, offers
partial protection, cutting episodes of malaria in babies and toddlers in half.
2012 — Novel Ad26MVA
vaccine provides
protection against SIV — Results found Ad26 / MVA
vaccine combinations can provide
partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys.
Results from a recent study show that novel
vaccine combinations can provide
partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys.
«
Vaccines that contain outdated strains of influenza may provide only
partial clinical
protection, and may result in nasal shedding of the virus, oftentimes as much as an unvaccinated horse, thus putting other horses at risk.»
In these cases, the
vaccine may give some «cross-
protection» or
partial protection, but
protection may not be complete.
In a parvo
vaccine trial conducted by Dr Ronald D Schultz, head of pathobiology at Wisconsin University, three out of six parvo
vaccine brands totally failed to give
protection; two gave only
partial protection; and only one was shown to be effective.